Association of Uric Acid, High-Sensitivity C-Reactive Protein, and 90-Day Risk of Poor Function Outcome in Patients with Ischemic Stroke or Transient Ischemic Attacks
Haoran Chen,Meng Wang,Lin Yang,Jiao Li,Zixiao Li
DOI: https://doi.org/10.2147/jir.s494487
IF: 4.5
2024-11-13
Journal of Inflammation Research
Abstract:Haoran Chen, 1 Meng Wang, 2, 3 Lin Yang, 1, 4 Jiao Li, 1, 4, &ast Zixiao Li 2, 3, 5, &ast 1 Institute of Medical Information/Library, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China; 2 Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China; 3 China National Clinical Research Center for Neurological Diseases, Beijing, People's Republic of China; 4 Key Laboratory of Medical Information Intelligent Technology, Chinese Academy of Medical Sciences, Beijing, People's Republic of China; 5 Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jiao Li, Institute of Medical Information/Library, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 3 Yabao Road, Chaoyang District, Beijing, 100020, People's Republic of China, Email Zixiao Li, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 119 West Road, Southern Fourth Ringroad, Fengtai District, Beijing, 100070, People's Republic of China, Email Aim: The interaction between inflammatory biomarkers (high-sensitivity C-reactive protein, hsCRP) and antioxidants (uric acid, UA) regarding prognosis after ischemic stroke or transient ischemic attack (TIA) remains inadequately explored. This study aimed to assess (1) the individual and joint effects of hsCRP and UA, and (2) the neuroprotective role of UA in patients with elevated hsCRP levels concerning poor functional outcomes at 90 days. Methods: A prospective cohort study was conducted involving 2140 consecutive ischemic stroke or TIA patients with hsCRP and UA levels. The primary outcome was defined as a poor functional outcome, indicated by a modified Rankin Scale (mRS) score of 3– 6 at 90 days, with a shift in the mRS score as a secondary outcome. Logistic regression and propensity score (PS) analyses were employed to ensure robustness. Results: Poor functional outcome occurred in 345 (16.1%) patients. Individual effects found that the highest quartiles of hsCRP (adjusted OR = 3.090; 95% CI 2.150– 4.442) and UA (adjusted OR = 0.671; 95% CI 0.551– 0.883) were associated with increased or decreased risk of poor functional outcome, respectively. Joint effects (adjusted OR = 3.994; 95% CI 2.758– 5.640) between hsCRP and UA on the primary outcome were more apparent in patients with high hsCRP levels (hsCRP > 1.60 mg/L) and low UA levels (UA ≤ 291.85 μmol/L). For the patients with high hsCRP levels, patients with low UA levels had a higher risk of primary and secondary outcomes, compared with those with high UA levels, after unadjusted or adjusted for hsCRP. Similar and reliable results were observed in PS-based models. Conclusion: In patients with ischemic stroke or TIA, joint high levels of hsCRP and low UA levels significantly correlate with increased risk of poor functional outcome at 90 days. In addition, high UA levels could reduce the risk of poor functional outcome for patients with high hsCRP levels. Keywords: biomarkers, ischemic stroke, poor functional outcome, joint effects, neuroprotective effects Graphical Among neurological disorders, stroke is the leading cause of death and disability, with approximately 10 million individuals becoming permanently disabled and dying each year. 1 Ischemic stroke represents the most prevalent form of stroke, accounting for approximately 71% of all cases worldwide. 2 The consequences of ischemic stroke can be profound, often resulting in significant neurological deficits that adversely impact patients' quality of life. Survivors frequently experience challenges in mobility, speech, and cognitive function, which can hinder their ability to perform daily activities and maintain independence. 3 And the primary pathological basis of most ischemic strokes is atherosclerosis, supported by four key lines of evidence. 4 Moreover, accumulating evidence supports the inflammation is of key importance in the pathophysiology of atherosclerosis. 4–6 Many previous studies have reported that inflammatory biomarkers such as IL-1, IL-6, TNF-α and hsCRP are associated with an increased risk of poor prognosis of patients with ischemic stroke or TIA. 5,7,8 Among these, hsCRP is a widely studied non-specific inflammatory biomarker for ischemic stroke, and high levels are independently linked to an increased risk of rec -Abstract Truncated-
immunology